The Long-Term Results of Using Low-Concentration Atropine Eye Drops for Controlling Myopia Progression in Schoolchildren

2011 ◽  
Vol 27 (5) ◽  
pp. 461-466 ◽  
Author(s):  
Pei-Chang Wu ◽  
Yi-Hsin Yang ◽  
Po-Chiung Fang
Keyword(s):  
Long Term Results ◽  
Eye Drops ◽  
Myopia Progression ◽  
Low Concentration

scholarly journals The Effect of Long-Term Low-Dose Atropine on Refractive Progression in Myopic Australian School Children

2021 ◽  
Vol 10 (7) ◽  
pp. 1444
Author(s):  
William Myles ◽  
Catherine Dunlop ◽  
Sally A. McFadden
Keyword(s):  
Low Dose ◽  
High Dose ◽  
Eye Drops ◽  
Myopia Progression ◽  
At Risk Children ◽  
Slow Group ◽  
Blue Eyes ◽  
Global Population ◽  
Axial Growth

Myopia will affect half the global population by 2050 and is a leading cause of vision impairment. High-dose atropine slows myopia progression but with undesirable side-effects. Low-dose atropine is an alternative. We report the effects of 0.01% or 0.005% atropine eye drops on myopia progression in 13 Australian children aged between 2 and 18 years and observed for 2 years without and up to 5 years (mean 2.8 years) with treatment. Prior to treatment, myopia progression was either ‘slow’ (more positive than −0.5D/year; mean −0.19D/year) or ‘fast’ (more negative than −0.5D/year; mean −1.01D/year). Atropine reduced myopic progression rates (slow: −0.07D/year, fast: −0.25D/year, combined: before: −0.74, during: −0.18D/year, p = 0.03). Rebound occurred in 3/4 eyes that ceased atropine. Atropine halved axial growth in the ‘Slow’ group relative to an age-matched model of untreated myopes (0.098 vs. 0.196mm/year, p < 0.001) but was double that in emmetropes (0.051mm/year, p < 0.01). Atropine did not slow axial growth in ‘fast’ progressors compared to the age-matched untreated myope model (0.265 vs. 0.245mm/year, p = 0.754, Power = 0.8). Adverse effects (69% of patients) included dilated pupils (6/13) more common in children with blue eyes (5/7, p = 0.04). Low-dose atropine could not remove initial myopia offsets suggesting treatment should commence in at-risk children as young as possible.

scholarly journals Efficacy of myopia control by combination of orthokeratology and instillation of low-concentration atropine

The Eye ◽  
2019 ◽  
Vol 126 (2019-2) ◽  
pp. 22-30
Author(s):  
Elena Tarutta ◽  
Tatiana Verzhanskaya
Keyword(s):  
High Myopia ◽  
Inhibitory Effect ◽  
Myopia Progression ◽  
Noticeable Effect ◽  
Low Concentration ◽  
Biomechanical Changes ◽  
Positive Effect ◽  
Myopia Control ◽  
Ampli Tude

Majority of reports regarding methods of myopia control are devoted to the use of orthokeratology lens¬es (OKL) or atropine. The purpose of the study was to estimate the efficacy and safety of using OKL in com¬bination with instillation of 0.01% atropine drops for myopia control in children. Material and methods. Prospective cohort study in¬cluded 34 patients (68 eyes) aged 8 to 14 years old with acquired myopia. Groups with low (17 patients, 34 eyes), moderate (12 patients, 24 eyes) and high (5 patients, 10 eyes) myopia were identified and examined prior to and 6, 12 and 18 months after adding 0.01% atropine instillations to OKL wearing. To assess the degree of pro¬gression of myopia in dynamics the following parameters were evaluated: refraction (by Huvitz MRK 3100P, axial length (AL) by IOL-Master, “Carl Zeiss”, (Germany), ampli¬tude of accommodation (AA) by Grand Seiko WRK-5100K, positive-relative accommodation (PRA), pseudoaccom¬modation (PA) and annual gradient of progression (AGP). Results. The most noticeable effect was observed in patients with low myopia. In patients with low myopia, the rate of annual progression gradient decreased by 3.4 times by 18th month of atropine use; therefore a condition close to stabilization of myopia progression occurred. The data is statistically significant. In patients with moderate myopia, despite the de¬crease of the AGP within 6-month period of atropine use by 3.7 times, the increase of APG was observed by 12th month of atropine use, which continued until 18th month of observation. In spite of this, in comparison with baseline indices, the decrease in the rate of myo¬pia progression was obtained. The data is statistically significant. In patients with high myopia, change in the AGP was not ob¬served within the 6-month period of atropine use; afterwards, a gradual decrease in the rate of myopia progression was noted: AGP decreased by 1.2 times by 12th month. By 18th month of atropine use, AGP decreased by 1.5 times compared to its initial level. The data is statistically significant. Evidently, the inhibitory effect of OKL, which is de¬termined by optical factors such as peripheral myopic defocus, even in combination with atropine, is not suf¬ficient to halt the progression of high myopia, because of structural and biomechanical changes of the sclera. Conclusion. Based on the preliminary results ob¬tained, 100% efficacy of a long-term instillation of low-concentration atropine cannot be claimed, howev¬er, the positive effect does exist and therefore the study continues.

Long-term results of praziquantel therapy in neurocysticercosis

1987 ◽  
Vol 66 (3) ◽  
pp. 359-363 ◽  
Author(s):  
Clemente Robles ◽  
Ana Maria Sedano ◽  
Noe Vargas-Tentori ◽  
Sonia Galindo-Virgen
Keyword(s):  
Cerebrospinal Fluid ◽  
Intracranial Hypertension ◽  
Tissue Damage ◽  
Long Term Results ◽  
Content Type ◽  
Low Concentration ◽  
Praziquantel Treatment ◽  
Fine Print

✓ The long-term results of praziquantel therapy in 141 patients with neurocysticercosis are presented. Seventy-five patients (53%) were considered to be cured because the cysts or nodules disappeared or became calcified following praziquantel treatment and the patients were asymptomatic at the end of a 5-year follow-up period. An additional 35 patients (24.8%) improved clinically and radiographically. The intraventricular Cysticercus cysts of five patients in this group were not affected by praziquantel and had to be surgically removed. The remaining 31 patients (21.9%) were unchanged or became worse probably because, prior to therapy, Cysticercus larvae had caused tissue damage. The fact that praziquantel did not affect intraventricular cysts suggests a low concentration of the drug in the cerebrospinal fluid. Surgery continues to be an important tool in the treatment of cysticercosis to remove parasites that do not respond to praziquantel therapy as well as for the relief of intracranial hypertension.

scholarly journals The Effects of 0.01% Atropine on Adult Myopes’ Contrast Sensitivity

2021 ◽  
Vol 15 ◽  
Author(s):  
Ziyun Cheng ◽  
Jianhui Mei ◽  
Suqi Cao ◽  
Ran Zhang ◽  
Jiawei Zhou ◽  
...  
Keyword(s):  
Contrast Sensitivity ◽  
Low Dose ◽  
Randomized Study ◽  
Eye Drops ◽  
Short Term ◽  
Myopia Progression ◽  
Significant Interaction Effect ◽  
Corrected Visual Acuity ◽  
To Receive

PurposeAtropine at a low concentration is considered a safe and effective treatment to mitigate myopia progression. However, the potential unwanted side effects of administering atropine at a low dose on visual functions other than best corrected visual acuity has not been investigated. In this study, we investigate the short-term (12,16, and 20 h) and long-term (1, 2, and 4 weeks) effects of 0.01% atropine (i.e., 0.1 mg/ml) on contrast sensitivity (CS) in patients with myopia.MethodsThirty adults (23.33 ± 2.93 years old) with myopia between -1.00 and -6.00 diopters (D), astigmatism of -1.50 D or less, and anisometropia of 1.00 D or less, participated in this prospective, masked, placebo-controlled, randomized study. The participants were randomly assigned to receive 0.01% atropine or polyvinyl alcohol eye drops once nightly to both eyes for four weeks. CS was measured binocularly at baseline and 12, 16, 20 h, 1, 2, and 4 weeks after the first use of the eye drops.ResultsThere was no statistically significant differences of CS found between atropine and placebo-controlled groups in both short-term and long-term. There was no statistically significant interaction effect found between the time and group.ConclusionWe demonstrated no significant deleterious effect of 0.01% atropine on adult myopes’ CS.

427: Long Term Results of Laparoscopic Retroperitoneal Lymph Node Dissection in Clinical Stage I NSGCT

2005 ◽  
Vol 173 (4S) ◽  
pp. 116-117
Author(s):  
Hannes Steiner ◽  
Reinhard Peschel ◽  
Tilko Müller ◽  
Christian Gozzi ◽  
Georg C. Bartsch ◽  
...  
Keyword(s):  
Lymph Node ◽  
Lymph Node Dissection ◽  
Clinical Stage ◽  
Stage I ◽  
Long Term Results ◽  
Retroperitoneal Lymph Node Dissection ◽  
Node Dissection ◽  
Retroperitoneal Lymph Node
Sign in / Sign up

Export Citation Format

Share Document